Insulin resistance is tightly linked to NAFLD, particularly in those with Type 2 Diabetes. In this video, Prof. Michael Roden, Germany discusses this link, its origins that can inherited or acquired. He also sheds light on the consequences of insulin resistance.
NASH is associated with cardiovascular diseases and cardiovascular mortality. Prof Rosano, UK discusses the prevalence, risks and economic costs of NAFLD and NASH. He sheds lights on the risk of obesity that induces many changes. He also reviews countries with higher prevalence, age characteristics and the incidence and progression of the disease

The prevalence, risks and costs of NASH

, by

NASH is associated with cardiovascular diseases and cardiovascular mortality. Prof Rosano, UK discusses the prevalence, risks and economic costs of NAFLD and NASH. He sheds lights on the risk of obesity that induces many changes. He also reviews countries with higher prevalence, age characteristics and the incidence and progression of the disease

Prof Bedossa discusses the definition of NAFLD / NASH and the role of liver biopsy. Liver biopsy cannot be used as a screening tool but is essential in clinical trials. To be useful, it has to be of a good quality and optimised. Prof Bedossa shares best practices in this regard.
Prof Bedossa discusses the definition of NAFLD / NASH and the role of liver biopsy. Liver biopsy cannot be used as a screening tool but is essential in clinical trials. To be useful, it has to be of a good quality and optimised. Prof Bedossa shares best practices in this regard.
In INAFLD, the liver is both victim and motor of a multisystem disease. Liver disease is not limited to the liver itself but has an impact on glycemic control in the body. Prof. Tacke discusses this vicious cycle and how NAFLD may add to coexisting risk factors and is predictor of morbidity and mortality. He shows why this is also important to develop new treatment strategies
In NAFLD/NASH clinical trials, liver biopsy is mandatory to assess eligibility and primary endpoints. It requires a lot of knowledge and skills to stage fibrosis and grade activity. Prof. Frank Bedossa discusses these important topics, as well as the different scores such as the NAFLD activity score (NAS) and the Steatosis Activity Fibrosis score (SAF).
2020 started with an important discussion about the terminology to be used regarding Non Alcoholic Fatty Liver Disease (NAFLD). In this exclusive interview for the PanNASH web site, Prof Sven Francque discusses the rationale of this change and the possible impact in clinical practice